BDA Partners is pleased to announce that its client, Advanced MedTech Holdings (\u201cAMTH\u201d), a subsidiary of Temasek, has acquired a majority interest in Shenzhen Wikkon Precision Instruments (\u201cWIKKON\u201d), China\u2019s market-leader in urology and shock wave therapy devices. AMTH expects to acquire the remaining shares of WIKKON by the end of 2022.<\/p>\n\n\n\n
BDA Partners was the exclusive financial advisor to AMTH on the transaction.<\/p>\n\n\n\n
The acquisition will significantly strengthen AMTH\u2019s direct presence in China. Combining the expertise of the leading German medical device company, Dornier MedTech, AMTH\u2019s wholly owned subsidiary, with the innovative capabilities of WIKKON, AMTH will be able to offer physicians access to an expanded product portfolio, and build up a high potential platform for the development of a global value segment in urology.<\/p>\n\n\n\n
Abel Ang, Group Chief Executive of Advanced MedTech, said: \u201cWe are now uniquely placed to aggressively grow in China\u2019s sizeable market, which is best served by domestically produced devices. Advanced MedTech\u2019s integrated urology platform is accelerated by WIKKON\u2019s significant R&D, manufacturing, supply chain, and installed base of units. Our newly combined portfolio will allow us to serve urology customers seeking value-oriented solutions right through to premium-oriented customers globally.\u201d <\/p>\n\n\n\n
Chen Ming, Founder and Chairman of WIKKON, said:\u201cWe are excited to become part of the Advanced MedTech group. By combining our expertise on innovative technology, research and reach, we will be able to significantly expand our solutions to healthcare professionals all over the world.\u201d<\/p>\n\n\n\n
Jeffrey Wang, Partner and Co-Head of Shanghai, BDA Partners, said: \u201cWe’re delighted to advise Advanced MedTech on this highly strategic transaction, which will strengthen its multinational presence and capture additional share in China\u2019s fast growing medical device sector. This transaction demonstrates BDA\u2019s expertise in cross-border M&A, helping clients identify and unlock opportunities to deepen their localisation in China, and our ability to execute deals in challenging external environments.\u201d <\/p>\n\n\n\n
Andrew Huntley, Managing Partner and Global Head of Healthcare, BDA Partners, added: \u201cChina now accounts for about 20% of the global medical device market, and has been growing at about 20% per year. This share will continue to rise supported by an aging population, increasing disposable income, and on-going healthcare service upgrades in hospitals and clinics throughout China. It’s an attractive market for multinational medtech players, but a challenging one to enter, so we’re excited to have helped Advanced MedTech on this transaction.\u201d<\/p>\n","protected":false},"featured_media":12957,"template":"","class_list":["post-12952","transaction","type-transaction","status-publish","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n